Markers and Time Course of Neurodegenerative Risk With Androgen Deprivation Therapy

摘要

The overall objective of this research program was to understand whether androgen deprivation therapy (ADT) decreases the quality of survival by amplifying age-related cognitive decline and increasing the risk for neurodegenerative disease. This report summarizes the entire study period. This study demonstrated the use of multiple forms of neuroimaging to examine potential neurotoxicity of ADT. Brain activity did not differ between men who were or were not on ADT. White matter integrity, particularly in the occipital region does appear to be lower in men on ADT. Quantitative T1 shows an expected age-related increase in both grey and white matter, but ADT does not affect this magnetic resonance measure of macromolecular content. Men on ADT did not meet the criteria for early Alzheimer s disease. While still in the clinically normal range, men on ADT reported more depression and more confusion than men who were not on ADT, and additional data (POMS, FAQ, FACT-P) suggest malaise is particularly difficult for the men early in ADT treatment.